WNT5A and breast cancer: In good agreement with our assumption, it was demonstrated that treatment of WNT5A-lacking breast cancer cells with Foxy5 reduces the metastatic spread of breast cancer cells by 70–80% in an orthotopic mouse model, highlighting its therapeutic potential as an anti-metastatic drug candidate.